{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:40:01Z","timestamp":1772005201489,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2003,5,27]],"date-time":"2003-05-27T00:00:00Z","timestamp":1053993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1038\/sj.bjc.6600989","type":"journal-article","created":{"date-parts":[[2003,5,27]],"date-time":"2003-05-27T17:10:29Z","timestamp":1054055429000},"page":"1669-1674","source":"Crossref","is-referenced-by-count":4,"title":["Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer"],"prefix":"10.1038","volume":"88","author":[{"given":"A","family":"Lortholary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Delozier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Monnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tubiana-Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Ch","family":"Riffaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Besson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Gamelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,5,27]]},"reference":[{"key":"BF6600989_CR1","first-page":"438","volume":"19","author":"AM Alberti","year":"2000","unstructured":"Alberti AM (2000) A phase II study of docetaxel (T) and carboplatin (CBP) as second line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19: 438 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600989_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00001813-199506000-00001","volume":"6","author":"MC Bissery","year":"1995","unstructured":"Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere\u00ae): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6: 339\u2013355","journal-title":"Anticancer Drugs"},{"key":"BF6600989_CR3","unstructured":"Bonneterre J, Roche H, Monnier A, Fargeot P, Namer M, Guastalla JP, Rios M, Serin D, Culine S, Tubiana M, Eymard JC, Assadourian S (1998) Docetaxel versus 5 fluorouracil\u2013vinorelbine in patients with metastatic breast cancer as second line chemotherapy: a phase III study. Proceedings of the 21st Annual San Antonio Breast Cancer Symposium 223 (abstract)"},{"key":"BF6600989_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/0959-8049(93)90527-M","volume":"29A","author":"J Carmo-Pereira","year":"1993","unstructured":"Carmo-Pereira J, Costa FO, Henriques E (1993) Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. Eur J Cancer 29A: 1814\u20131816","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"BF6600989_CR5","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1097\/00000421-199012001-00009","volume":"13","author":"B Chevallier","year":"1990","unstructured":"Chevallier B, Fumoleau P, Kerbrat P, Monnier A, Roche H, Goudier MJ, Herait P (1990) Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer. Am J Clin Oncol 13(Suppl 1): S40\u2013S43","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 12","key":"BF6600989_CR6","first-page":"12","volume":"25","author":"J Crown","year":"1998","unstructured":"Crown J (1998) Evolution in the treatment of advanced breast cancer. Semin Oncol 25(Suppl 12): 12\u201317","journal-title":"Semin Oncol"},{"key":"BF6600989_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.1996.416","volume":"74","author":"V Di\u00e9ras","year":"1996","unstructured":"Di\u00e9ras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL (1996) A multicentre phase II study of docetaxel 75\u2009mg\/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 74: 650\u2013656","journal-title":"Br J Cancer"},{"key":"BF6600989_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF00666065","volume":"30","author":"S Fine","year":"1994","unstructured":"Fine S, Erlichman C, Kaizer L, Warr D, Gadalla T (1994) Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Res Treat 30: 205\u2013209","journal-title":"Breast Cancer Res Treat"},{"key":"BF6600989_CR9","first-page":"418","volume":"19","author":"A Gomez","year":"2000","unstructured":"Gomez A, Cruz JJ, Garcia-Palomo A, Arizcun A, Pujol E, Diz P, Martin G, Sanchez E, del Barco E, Lopez Y, Sanchez P (2000) Docetaxel and navelbine every 14-days in patients with metastatic breast cancer after using anthracyclines. Final results.. Proc Am Soc Clin Oncol 19: 418 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600989_CR10","first-page":"604","volume-title":"Breast Disease","author":"IC Henderson","year":"1991","unstructured":"Henderson IC (1991) Chemotherapy for metastatic disease of breast cancer. In Breast Disease, Harris J, Hellman S, Henderson IC, Kinne DW (eds) (2nd edn) pp 604\u2013665. Philadelphia, PA: Lippincott"},{"key":"BF6600989_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"Suppl 13","key":"BF6600989_CR12","first-page":"S13","volume":"24","author":"D Khayat","year":"1997","unstructured":"Khayat D, Antoine E (1997) Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol 24(Suppl 13): S13\u2013S19","journal-title":"Semin Oncol"},{"key":"BF6600989_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1023\/A:1012247311419","volume":"12","author":"LR Laufman","year":"2001","unstructured":"Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N et al (2001) Monthly docetaxel and weekly gemcitabine in patients with metastatic breast cancer: A phase II trial. Ann Oncol 12: 1259\u20131264","journal-title":"Ann Oncol"},{"key":"BF6600989_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(00)00176-3","volume":"36","author":"A Lortholary","year":"2000","unstructured":"Lortholary A, Maillart P, Delva R, Boisdron-Celle M, Perard D, Vernillet L, Besenval M, Gamelin E (2000) Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study. Eur J Cancer 36: 1773\u20131780","journal-title":"Eur J Cancer"},{"key":"BF6600989_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1008315723253","volume":"10","author":"D Mavroudis","year":"1999","unstructured":"Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, et al (1999) Salvage chemotherapy in anthracycline-pretreated breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 10: 211\u2013215","journal-title":"Ann Oncol"},{"key":"BF6600989_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","volume":"17","author":"JM Nabholtz","year":"1999","unstructured":"Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschonos L, Douma J et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413\u20131424","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"BF6600989_CR17","first-page":"25","volume":"11","author":"J-M Nabholtz","year":"1997","unstructured":"Nabholtz J-M, Smylie M, Mackey J, Paterson A, Noel D, al-Tweigeri, Janowska A, Delorme F, Riva A (1997) Docetaxel\/doxorubicin\/cyclophosphamide in the treatment of metastatic breast cancer. Oncology 11(Suppl 6): 25\u201327","journal-title":"Oncology"},{"key":"BF6600989_CR18","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O'Shaughnessy","year":"2002","unstructured":"O'Shaughnessy J, Miles D, Vukelja S, Moiscyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20(12): 2812\u20132823","journal-title":"J Clin Oncol"},{"key":"BF6600989_CR19","first-page":"435","volume":"19","author":"D Pectasides","year":"2000","unstructured":"Pectasides D, Papadimitriou C, Aravantinos G, Kosmidis P, Papakostas P, Briassoulis E, Kalofonos H, Bafaloukos D, Christodoulou C, Razis E, Gogas H, Timotheadou H, Dimopoulous M (2000) Docetaxel and navelbine as first line chemotherapy in advanced breast cancer. A phase II study of Hellenic Cooperative Oncology Group. Proc Am Soc Clin Oncol 19: 435 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600989_CR20","first-page":"452","volume":"19","author":"V Pescia","year":"2000","unstructured":"Pescia V, Bordenave HR, Foglia S, Litchvaky A, Wull F, Belloqui D, Gramuglia M, Arteaga C (2000) Taxotere (T) and cisplatin (C) in anthracycline-pretreated advanced breast cancer: preliminary results. Proc Am Soc Clin Oncol 19: 452 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600989_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1023\/A:1008356025108","volume":"10","author":"T Petit","year":"1999","unstructured":"Petit T, Aylesworth C, Burris H, Ravdin P, Rodriguez G, Smith L et al (1999) A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol 10: 223\u2013229","journal-title":"Ann Oncol"},{"key":"BF6600989_CR22","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","volume":"13","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879\u20132885","journal-title":"J Clin Oncol"},{"key":"BF6600989_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/mpo.2950200410","volume":"20","author":"T Saphner","year":"1992","unstructured":"Saphner T, Tormey DC, Carey P (1992) Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study. Med Pediatr Oncol 20: 321\u2013324","journal-title":"Med Pediatr Oncol"},{"key":"BF6600989_CR24","first-page":"427","volume":"17","author":"J Sj\u00f6str\u00f6m","year":"1998","unstructured":"Sj\u00f6str\u00f6m J, Mouridsen H, Pluzanska A, Ottosso LS, Bengtsson N, Ostenstad B, Mjaaland I, Malmstrom P, Bergh J, Wist E, Valvere V, Blomqvist C (1998) Taxotere versus methotrexate\u20135\u2013fluorouracil in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc Am Soc Clin Oncol 17: 427 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600989_CR25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","volume":"18","author":"JA Sparano","year":"2000","unstructured":"Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC (2000) Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18: 2369\u20132377","journal-title":"J Clin Oncol"},{"key":"BF6600989_CR26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1023\/A:1008318523058","volume":"10","author":"M Spielmann","year":"1999","unstructured":"Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A (1999) Docetaxel\u2013cisplatin combination chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10: 1457\u20131460","journal-title":"Ann Oncol"},{"key":"BF6600989_CR27","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","volume":"13","author":"V Valero","year":"1995","unstructured":"Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G et al (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886\u20132894","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BF6600989_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000227737","volume":"54","author":"AH Villalon","year":"1997","unstructured":"Villalon AH, De Guzman LM, Samson MC, Guancia AA, Fernando GY, Romana IB (1997) A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. Oncology 54(Suppl 1): 2\u20136","journal-title":"Oncology"},{"key":"BF6600989_CR29","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","volume":"330","author":"WC Wood","year":"1994","unstructured":"Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. New Engl J Med 330: 1253\u20131259","journal-title":"New Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600989","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:50:01Z","timestamp":1684414201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,27]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["BF6600989"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600989","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,27]]}}}